Marshall Wace LLP acquired a new stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 18,102 shares of the company's stock, valued at approximately $261,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Renaissance Technologies LLC lifted its stake in HUTCHMED by 18.4% during the 4th quarter. Renaissance Technologies LLC now owns 188,539 shares of the company's stock valued at $2,717,000 after acquiring an additional 29,239 shares in the last quarter. XY Capital Ltd bought a new position in shares of HUTCHMED during the fourth quarter valued at about $673,000. ABC Arbitrage SA purchased a new position in HUTCHMED during the fourth quarter worth about $500,000. Crossmark Global Holdings Inc. boosted its holdings in HUTCHMED by 10.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock worth $268,000 after purchasing an additional 1,799 shares during the last quarter. Finally, OLD Mission Capital LLC bought a new stake in HUTCHMED in the 4th quarter worth about $230,000. 8.82% of the stock is owned by institutional investors.
HUTCHMED Stock Down 1.9 %
Shares of NASDAQ:HCM traded down $0.28 during midday trading on Friday, reaching $14.26. The company had a trading volume of 41,591 shares, compared to its average volume of 102,731. HUTCHMED has a 52-week low of $11.51 and a 52-week high of $21.87. The company's 50 day moving average price is $14.74 and its 200 day moving average price is $15.41. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.
Analyst Ratings Changes
Separately, StockNews.com upgraded HUTCHMED from a "hold" rating to a "buy" rating in a research note on Friday, March 21st.
Check Out Our Latest Research Report on HCM
HUTCHMED Profile
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Further Reading
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
